Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Continuous Versus Syncopated Dosing of CC-5013 for the Treatment of Refractory Multiple Myeloma

NCT00051116 is registered in ClinicalTrials.gov with Celgene Corporation as lead sponsor.

NCT NCT00051116
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00051116 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Continuous Versus Syncopated Dosing of CC-5013 for the Treatment of Refractory Multiple Myeloma
Lead sponsor
Celgene Corporation
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2002
Completion date
October 31, 2006
Enrollment
100 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma